Table of Contents Author Guidelines Submit a Manuscript
Case Reports in Hematology
Volume 2014, Article ID 937203, 4 pages
http://dx.doi.org/10.1155/2014/937203
Case Report

CNS Involvement in AML Patient Treated with 5-Azacytidine

1Second Department of Internal Medicine and Research Institute, Athens University Medical School, Attikon University General Hospital, 1 Rimini Street, 12462 Athens, Greece
2Iatropolis Magnetic Tomography SA, 15231 Athens, Greece
3Department of Cytopathology, Medical School Attikon University Hospital, University of Athens, 12462 Athens, Greece

Received 12 April 2014; Revised 30 June 2014; Accepted 18 July 2014; Published 14 August 2014

Academic Editor: Salah Aref

Copyright © 2014 Diamantina Vasilatou et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. J. Cortes, “Central nervous system involvement in adult acute lymphocytic leukemia,” Hematology/Oncology Clinics of North America, vol. 15, no. 1, pp. 145–162, 2001. View at Publisher · View at Google Scholar · View at Scopus
  2. E. Crespo-Solis, X. López-Karpovitch, J. Higuera, and B. Vega-Ramos, “Diagnosis of acute leukemia in cerebrospinal fluid (CSF-acute leukemia),” Current Oncology Reports, vol. 14, no. 5, pp. 369–378, 2012. View at Publisher · View at Google Scholar · View at Scopus
  3. M. Bommer, S. von Harsdorf, H. Döhner, D. Bunjes, and M. Ringhoffer, “Neoplastic meningitis in patients with acute myeloid leukemia scheduled for allogeneic hematopoietic stem cell transplantation,” Haematologica, vol. 95, no. 11, pp. 1962–1972, 2010. View at Publisher · View at Google Scholar · View at Scopus
  4. D. A. Pollyea, H. E. Kohrt, L. Gallegos et al., “Safety, efficacy and biological predictors of response to sequential azacitidine and lenalidomide for elderly patients with acute myeloid leukemia,” Leukemia, vol. 26, no. 5, pp. 893–901, 2012. View at Publisher · View at Google Scholar · View at Scopus
  5. C. Nabhan, L. M. Rundhaugen, M. B. Riley et al., “Phase II pilot trial of gemtuzumab ozogamicin (GO) as first line therapy in acute myeloid leukemia patients age 65 or older,” Leukemia Research, vol. 29, no. 1, pp. 53–57, 2005. View at Publisher · View at Google Scholar · View at Scopus
  6. C. Pui and S. C. Howard, “Current management and challenges of malignant disease in the CNS in paediatric leukaemia,” The Lancet Oncology, vol. 9, no. 3, pp. 257–268, 2008. View at Publisher · View at Google Scholar · View at Scopus
  7. F. Shihadeh, V. Reed, S. Faderl et al., “Cytogenetic profile of patients with acute myeloid leukemia and central nervous system disease,” Cancer, vol. 118, no. 1, pp. 112–117, 2012. View at Publisher · View at Google Scholar · View at Scopus
  8. H. Chang, J. Brandwein, Q. Yi, K. Chun, B. Patterson, and B. Brien, “Extramedullary infiltrates of AML are associated with CD56 expression, 11q23 abnormalities and inferior clinical outcome,” Leukemia Research, vol. 28, no. 10, pp. 1007–1011, 2004. View at Publisher · View at Google Scholar · View at Scopus
  9. N. Tiftik, Z. Bolaman, S. Batun et al., “The importance of CD7 and CD56 antigens in acute leukaemias,” International Journal of Clinical Practice, vol. 58, no. 2, pp. 149–152, 2004. View at Publisher · View at Google Scholar · View at Scopus
  10. H. Cheng, Y. Yang, W. Dai et al., “Acute leukemia presenting with blasts first found in the cerebrospinal fluid but not in the peripheral blood,” Journal of Clinical Neuroscience, vol. 17, no. 10, pp. 1252–1255, 2010. View at Publisher · View at Google Scholar · View at Scopus
  11. S. E. Mccormack and E. D. Warlick, “Epigenetic approaches in the treatment of myelodysplastic syndromes: clinical utility of azacitidine,” OncoTargets and Therapy, vol. 3, pp. 157–165, 2010. View at Google Scholar · View at Scopus